NCT00982566 - Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

December 31, 2010

Conditions

Lymphoid MalignancySolid Tumors

Interventions

DRUG

ABT-263

Part 1: Single (oral) dose of 250 mg of Formulation B1 vs. single (oral) dose of 250 mg of Formulation A

DRUG

ABT-263

Part 1 continued. Single (oral) dose of 250 mg of Formulation B2 vs. single (oral) dose of 250 mg of Formulation A

DRUG

ABT-263

Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A

DRUG

ABT-263

Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A